Boston Scientific outlook for 2026 weakened on October 28 as the medical device maker lowered its full-year earnings and sales growth forecasts and projected a fourth-quarter sales decline.

Boston Scientific outlook for 2026

The company now expects adjusted earnings of $3.16 to $3.18 per share for 2026, down from its previous forecast of $3.28 to $3.32.

In its third-quarter results release, Boston Scientific projected full-year reported net sales growth of approximately 4.25% and organic growth of approximately 3.75%. Its earlier outlook called for reported growth of 5.5% to 6.5% and organic growth of 5% to 6%.

For the fourth quarter, Boston Scientific expects adjusted earnings of $0.77 to $0.79 per share and a sales decline of 1% to 3% on both a reported and organic basis, compared with a year earlier.

Third-quarter earnings and trading

Third-quarter net sales rose 1.5% year over year to $5.138 billion. Adjusted earnings per share fell to $0.73 from $0.75, while GAAP net income attributable to common stockholders declined to $582 million from $755 million.

Chief Executive Officer Mike Mahoney described the year as challenging and said employees had worked to restore operations following a cybersecurity incident. The company identified disruptions from the incident as a risk to its operations and financial results.

Boston Scientific shares traded at $43.91 in pre-market trading on October 28, down $1.17, or 2.59%.

Read More News

More FinanceVelix news

Disclaimer

This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.